Recent statements from Cosmetic Ingredient Review leadership and Expert Panel members affirming the safety of parabens, while their latest review of the ingredients is ongoing, undermine the program’s credibility, according to NGO Women’s Voices for the Earth. CIR Director Bart Heldreth responds.
NGO Women’s Voices for the Earth is convinced that the industry-funded Cosmetic Ingredient Review is inherently conflicted and that its latest review of parabens is a case in point.
Join thousands of industry professionals who rely on HBW Insight for daily insights
Already a subscriber?
Engaging with EU member state legislators, stressing the impact of national EPR systems on the accessibility, availability, and affordability of medicines, reformulating products to reduce their financial contribution, and lobbying for expanding the scope of EPR schemes to include other polluting industries are all ways that the European consumer health industry can try and influence the way that the revised Urban Wastewater Treatment Directive is transposed into national legislation, law firm Mason Hayes & Curran explains.
France's food safety regulator ANSES is proposing a reproductive toxicity category 1B classification for CBD under the EU's CLP regulation, which would mean an effective ban on CBD in cosmetics and foods. However, French hemp industry association UIVEC hopes that new evidence coming out of a European Commission review will put the issue to bed before it gets that far.
Reclassifying ethanol as a carcinogenic, mutagenic, or reprotoxic substance - something the European Chemicals Agency seems likely to do in the near future - would be “tantamount to a de facto ban” with “fatal consequences” for medical care in Germany, says Pharma Deutschland in a joint paper with 13 other German healthcare industry associations.
Two AESGP papers reviewing the evidence for AMR risk associated with a range of OTC antifungals and antivirals conclude there is litte to no risk associated with the responsible self-care use of such medicines.
In discussing FDA’s adverse event monitoring, Makary also seemed to falsely imply the agency did not fully investigate the myocarditis signal with COVID-19 vaccines.
HHS Secretary Robet F. Kennedy Jr. and FDA Commissioner Marty Makary to announce planned changes as “a major step forward” as part of Kennedy’s “Make America Healthy Again” campaign President Trump has adopted for his administration.
Revlon Group Holdings LLC announces Dana Medema, formerly VP and head of Personal Health in North America for Philips, will serve as president, North America. Separately, Shiseido Company, Ltd. reports Ron Gee has resigned as Americas Region CEO and will be replaced on an interim basis by Alberto Noe.
